SCHEMBL12040460

SCHEMBL12040460

CC(C)(C)[C@H](NC(=O)OCc1ccccc1)C(=O)N1CCC[C@H]1C=O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 4/20 0.54
▸ CASP1 P29466 1/20 0.49
▸ CASP3 P42574 1/20 0.49
▸ CASP2 P42575 1/20 0.49
▸ CASP4 P49662 1/20 0.49
▸ CASP5 P51878 1/20 0.49
▸ CASP7 P55210 1/20 0.49
▸ CASP9 P55211 1/20 0.49
▸ CASP8 Q14790 1/20 0.49
▸ CASP10 Q92851 1/20 0.49
▸ STAT6 P42226 2/20 0.47
▸ ACE P12821 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ CTSL P07711 1/20 0.46
▸ CTSB P07858 1/20 0.46
▸ CTSK P43235 1/20 0.46
▸ CCR1 P32246 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18620597 0.87 ACE (0.60) PREPCASP1CASP3CASP2CASP4
SCHEMBL9814469 0.87 CAPN1 (0.59) PREPCASP1CASP3CASP7CASP8
SCHEMBL20484674 0.87 ACE (0.60) PREPCASP1CASP3CASP2CASP4
SCHEMBL9814470 0.87 CAPN1 (0.59) PREPCASP1CASP3CASP7CASP8
SCHEMBL10607790 0.86 PREP (0.71) PREPACEALDH1A1CYP3A4TSHR
SCHEMBL10607793 0.86 PREP (0.71) PREPACEALDH1A1CYP3A4TSHR
SCHEMBL22209492 0.85 ALDH1A1 (0.61) PREPCASP1CASP3CASP2CASP4
SCHEMBL18620865 0.85 ALDH1A1 (0.61) PREPCASP1CASP3CASP2CASP4
SCHEMBL12023625 0.83 ALDH1A1 (0.53) PREPCASP1CASP3CASP2CASP4
SCHEMBL478151 0.83 ALDH1A1 (0.53) PREPCASP1CASP3CASP2CASP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329662-B2 Prodrug of an ICE inhibitor Vertexd Pharmaceuticals Incorporated (US) 2012-12-11 — — US disclosed
US-20110301096-A1 PRODRUG OF AN ICE INHIBITOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-12-08 — — US disclosed
US-7381827-B2 5-Ethoxy-4-(1-(benzyloxycarbonyl)-2-pyrrolidinylcarbonylamino)-5H-furan-2-one; purification by chromatography, selectively crystallization, or dynamic crystallization; useful for preparing caspase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301096-A1 PRODRUG OF AN ICE INHIBITOR CASP1, MCL1, IL1B PREP 455/4885CASP1 1/4885CASP3 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback